@RaabMarc

Clinician and scientist focusing on multiple myeloma. Chair, GMMG study group. Tweets are my own. @HDMyeloma @ukhd @dkfz

 Heidelberg, Deutschland
Joined April 2023
  • Tweets194
  • Following102
  • Followers460
23Media
Marc Raab, MD, discussed cure in the context of the GEM14MAIN & MajesTEC-5 data shared during #IMS26. He also summarized studies on improving CAR-T safety and monitoring/managing bone disease during the Highlights session. @RaabMarc
1
1
2
296
#IMS26 Tal-DR in newly diagnosed ASCT-eligible myeloma. More excellent MajesTEC-5 by @RascheLeo @RaabMarc et al! 👏 No issues with SC collection. Excellent response 👇🏼. 15% ataxia (all low-grade & recovering) - perhaps combo Tx, or truly more common as tal enters earlier lines?
13
26
1,099
Marc S. Raab retweeted
Heidelberg Myeloma@HDMyeloma
Sep 12
This weekend, we bid farewell to Hartmut Goldschmidt, who will retire from his academic positions at the end of the month. To celebrate 35 years of @HDMyeloma, 30 years of #GMMG, a large crowd joined us for a dedicated symposium with long-standing partners and friends. #mmsm
6
15
591
Lively discussion on functional high risk myeloma at the IMS Genomics Workshop 2026 in Warsaw, Poland #mmsm @MyMKaiser @BrunoPaiva_UNAV @szusmani @NBahlis @nickbolli @FrancescoMaura4 @IrenemGhobrial
Myeloma Society
@Myeloma_Society
Jul 2
Mark your calendars for the 4th Annual Workshop on Genomics. 📅 July 10-11 in Warsaw, Poland. Register today for in-person or virtual attendance! ow.ly/GNtg50YQrjx

4th Annual Workshop on Genomics - International Myeloma Society

Agenda

myelomasociety.org
3
2
17
5,033
Marc S. Raab retweeted
Saurabh Zanwar
@ZanwarSaurabh
Jun 28
GMMG-HD10/MajesTEC-5 represents an important and likely a watershed moment in myeloma induction and consolidation therapy! Amazing early and deep responses (100% MRD neg rates!!) 👏👏 @RascheLeo @RaabMarc et al. AntiCD38-based quadruplets set the bar pretty high for early PFS rates PFS and now we have a worthy challenger! Whether this eventually displaces autologous transplant or not, one thing is for sure—BCMA bispecifics in induction will certainly make all of us think like transplanters when it comes to our infectious disease game (>35% Gr3 infections, 6% CMV reactivation). Biggest question that will need answering is whether everyone need a BCMA TCE upfront and for how long? nature.com/articles/s41591-0…

Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a...

Nature Medicine - In the ongoing phase 2 GMMG-HD10/DSMM-XX (MajesTEC-5) trial in patients with transplant-eligible, newly diagnosed multiple myeloma, induction with the BCMA×CD3 bispecific...

nature.com
3
10
1
24
3,813
Love seeing triple-digit MRD neg percentages 🤩 Congrats @RaabMarc et al on excellent MajesTEC-5 @NatureMedicine paper! bsAb-based induction in ND myeloma - may well obviate ASCT. Top panel = ITT, bottom = MRD-evaluable. Kudos to authors for reporting both sets like this.
Robert Z. Orlowski@Myeloma_Doc
Jun 26
#Myeloma Paper of the Day: Teclistamab-based induction in TE NDMM shows MRD- CR rate 91.8% (45/49) by pre-maintenance timepoint, 100% in evaluable samples & post-induction cycle 3 (10-5 (46/46)), 6 (10-5 (46/46) & 10-6 (46/46)); ORR was 100%: pubmed.ncbi.nlm.nih.gov/4235…. #mmsm
12
47
5,224
#Myeloma Paper of the Day: Teclistamab-based induction in TE NDMM shows MRD- CR rate 91.8% (45/49) by pre-maintenance timepoint, 100% in evaluable samples & post-induction cycle 3 (10-5 (46/46)), 6 (10-5 (46/46) & 10-6 (46/46)); ORR was 100%: pubmed.ncbi.nlm.nih.gov/4235…. #mmsm
2
28
3
47
8,978
Marc S. Raab retweeted
nizar jacques bahlis
@NBahlis
Jun 26
Anti-BCMA TCE in newly diagnosed myeloma. New era is here, end of HCT? congrats @RaabMarc @RascheLeo nature.com/articles/s41591-0…

Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a...

Nature Medicine - In the ongoing phase 2 GMMG-HD10/DSMM-XX (MajesTEC-5) trial in patients with transplant-eligible, newly diagnosed multiple myeloma, induction with the BCMA×CD3 bispecific...

nature.com
1
24
5
43
15,648
Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy @BCD_AACR aacrjournals.org/bloodcancer…

Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing...

To weigh potential risks and benefits of bispecific antibody therapy for individual RRMM patients' therapy, this study compares performance of three risk-scoring systems established for CAR T-cell...

aacrjournals.org
1
5
12
814
Work and life need to be balanced @MyMKaiser #EMN2026
2
1
17
794
Now online: Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy doi.org/10.1158/2643-3230.BC…
1
4
1
13
1,145
Fascinating - albeit a little terrifying - @LeukemiaJnl work by 🇩🇪 How does GPRC5D loss affect surviving myeloma #MMsm clones? Here, remaining cells appear to be more aggressive. Will be important to validate / rebut as talquetamab moves into earlier lines... hopefully soon!
2
9
1
30
3,149
Marc S. Raab retweeted
Eddie Cliff@Eddie_Cliff
Apr 3
In this week's issue of @BloodPortfolio, our study of global access to CAR T, led by Alex Ge. Thanks to Blood editors for making it a plenary paper! Free access link: authors.elsevier.com/a/1mt5a… Thanks @kjmeetswrld for the thoughtful commentary ashpublications.org/blood/ar…
22
1
58
9,290
5/5 Dr Marc Raab On exciting data from trispecifics and NK engagers
2
2
278
Insightful algorithm for risk-informed management of newly diagnosed #MultipleMyeloma in the era of Quads upfront by @MyMKaiser @ESHaematology
1
7
35
1,923
Day 2 of #ESHMM26 6th session on personalising treatment in myeloma Focusing on high-risk disease, CAR-T and bispecific toxicities, MRD-directed strategies, & precision medicine @MyMKaiser @NicoGagelmann @End_myeloma Dr Marc Raab #ESHCONFERENCES
4
14
1,482
Marc S. Raab retweeted
Daniel Auclair
@AuclairDan
Mar 28
Provocative presentation by Dr. Mirco Friedrich @mircoscopy at @Myeloma_Society 7th Immune Effector on whether or not T-cell exhaustion exists in #myeloma #mmsm @NikhilMunshiMD @szusmani @NBahlis
Daniel Auclair
@AuclairDan
Mar 28
Big discussion this morning at @Myeloma_Society 7th Immune Effector Workshop on the “T-cell Mechanism That Shall Not Be Named” @szusmani @myelomaMD @NikhilMunshiMD @IrenemGhobrial @NBahlis #mmsm
1
8
27
4,143
Does ASCT still matter in the era of quadruplets? • PFS benefit remains • OS benefit unclear • Role at relapse = individualized 👉 With emerging T-cell therapies, sequencing will become even more complex. #EBMT25 #Myeloma
8
2
29
2,305
Marc S. Raab retweeted
Cristobal Frutos@chano_py
Mar 24
Other info: No beneflt from salvage HCT (if one was given in 1st response) vs continous Rd treatment (IMO) Careful about offering HCT at relapse (not given purposely in first response but "saved" for later stages) since attrition in MM up to 30% Remember best option 1st #EBMT26 – at Madrid, Spain
3
7
532
Marc S. Raab retweeted
Cristobal Frutos@chano_py
Mar 24
#EBMT26 Plenary Session on Multiple Myeloma Thats the slide Hopefully in the future we may stop offering HCT to patients It is very hard to endure for most patients Not yet though – at Madrid, Spain
1
4
1
16
1,139
Load more